Catalyst Total Stockholder Equity vs Property Plant Equipment Analysis
CPRX Stock | USD 14.89 0.21 1.43% |
Catalyst Pharmaceuticals financial indicator trend analysis is way more than just evaluating Catalyst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Catalyst Pharmaceuticals is a good investment. Please check the relationship between Catalyst Pharmaceuticals Total Stockholder Equity and its Property Plant Equipment accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
Total Stockholder Equity vs Property Plant Equipment
Total Stockholder Equity vs Property Plant Equipment Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Catalyst Pharmaceuticals Total Stockholder Equity account and Property Plant Equipment. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Catalyst Pharmaceuticals' Total Stockholder Equity and Property Plant Equipment is 0.48. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of Catalyst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Catalyst Pharmaceuticals' Total Stockholder Equity and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Catalyst Pharmaceuticals are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Total Stockholder Equity i.e., Catalyst Pharmaceuticals' Total Stockholder Equity and Property Plant Equipment go up and down completely randomly.
Correlation Coefficient | 0.48 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Property Plant Equipment
Most indicators from Catalyst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Catalyst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.At this time, Catalyst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 19.7 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.11 in 2024.
2023 | 2024 (projected) | Reconciled Depreciation | 24.4M | 25.6M | Net Interest Income | 1.8M | 1.0M |
Catalyst Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Catalyst Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Catalyst Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 112.4M | 192.4M | 237.8M | 375.6M | 471.9M | 495.5M | |
Total Stockholder Equity | 87.6M | 169.6M | 206.8M | 300.4M | 387.9M | 407.3M | |
Net Debt | (88.9M) | (130.2M) | (167.6M) | (294.5M) | (134.1M) | (127.4M) | |
Cash | 89.5M | 130.2M | 171.4M | 298.4M | 137.6M | 144.5M | |
Cash And Short Term Investments | 94.5M | 140.3M | 191.3M | 298.4M | 137.6M | 144.5M | |
Common Stock Shares Outstanding | 106.0M | 106.2M | 107.8M | 111.4M | 113.8M | 57.0M | |
Liabilities And Stockholders Equity | 112.4M | 192.4M | 237.8M | 375.6M | 471.9M | 495.5M | |
Other Stockholder Equity | 216.2M | 223.2M | 233.2M | 250.4M | 266.5M | 279.8M | |
Total Liab | 24.7M | 22.8M | 31.0M | 75.2M | 84.0M | 88.2M | |
Total Current Assets | 111.4M | 159.2M | 210.1M | 320.8M | 219.3M | 230.3M | |
Other Current Liab | 172.3K | 107.0K | 243K | 53.3M | 60.2M | 63.2M | |
Total Current Liabilities | 24.1M | 22.8M | 27.1M | 57.6M | 76.1M | 79.9M | |
Property Plant And Equipment Net | 1.0M | 129.8K | 4.0M | 3.6M | 3.7M | 3.9M | |
Retained Earnings | (128.7M) | (53.7M) | (26.3M) | 49.9M | 121.3M | 127.3M | |
Accounts Payable | 4.1M | 4.3M | 2.8M | 4.0M | 14.8M | 15.5M | |
Non Current Assets Total | 1.0M | 33.1M | 27.7M | 54.8M | 252.6M | 265.2M | |
Common Stock Total Equity | 103.4K | 103.8K | 103K | 105K | 120.8K | 66.6K | |
Property Plant And Equipment Gross | 1.0M | 129.8K | 4.0M | 3.6M | 4.4M | 4.6M | |
Accumulated Other Comprehensive Income | 9.5K | 31.3K | (148K) | 24K | 14K | 14.7K | |
Common Stock | 103.4K | 103.8K | 103K | 105K | 107K | 69.1K | |
Property Plant Equipment | 210.5K | 129.8K | 4.0M | 847K | 974.1K | 1.0M | |
Other Current Assets | 4.4M | 8.3M | 4.4M | 5.2M | 12.5M | 13.2M | |
Non Current Liabilities Total | 647.5K | 4.3M | 3.9M | 17.6M | 8.0M | 8.4M | |
Net Tangible Assets | 87.6M | 169.6M | 206.8M | 268.0M | 308.1M | 323.5M | |
Retained Earnings Total Equity | (160.6M) | (128.7M) | (26.3M) | 49.9M | 57.3M | 60.2M | |
Capital Surpluse | 211.3M | 216.2M | 233.2M | 250.4M | 288.0M | 169.1M | |
Inventory | 2.0M | 4.7M | 7.9M | 6.8M | 15.6M | 16.4M | |
Non Current Liabilities Other | 154.8K | 647.5K | 3.9M | 17.6M | 485K | 460.8K | |
Net Invested Capital | 87.6M | 169.6M | 206.8M | 300.4M | 387.9M | 201.8M | |
Net Working Capital | 87.3M | 136.5M | 183.0M | 263.2M | 143.3M | 147.7M | |
Capital Stock | 103.4K | 103.8K | 103K | 105K | 107K | 114.6K |
Catalyst Pharmaceuticals Investors Sentiment
The influence of Catalyst Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Catalyst. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Catalyst Pharmaceuticals' public news can be used to forecast risks associated with an investment in Catalyst. The trend in average sentiment can be used to explain how an investor holding Catalyst can time the market purely based on public headlines and social activities around Catalyst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Catalyst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Catalyst Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Catalyst Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Catalyst Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Catalyst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Catalyst Pharmaceuticals' short interest history, or implied volatility extrapolated from Catalyst Pharmaceuticals options trading.
Pair Trading with Catalyst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Catalyst Stock
0.66 | SBFMW | Sunshine Biopharma | PairCorr |
The ability to find closely correlated positions to Catalyst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Pharmaceuticals to buy it.
The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.